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We hypothesised that tumour necrosis factor-𝛼 (TNF-𝛼) may enhance receptor activator of nuclear factor-𝜅𝛽 ligand- (RANKL-)
mediated osteoclastogenesis in acute Charcot osteoarthropathy. Peripheral blood monocytes were isolated from 10 acute Charcot
patients, 8 diabetic patients, and 9 healthy control subjects and cultured in vitro on plastic and bone discs. Osteoclast formation
and resorption were assessed after treatment with (1) macrophage-colony stimulating factor (M-CSF) and RANKL and (2) M-
CSF, RANKL, and neutralising antibody to TNF-𝛼 (anti-TNF-𝛼). Resorption was measured on the surface of bone discs by image
analysis and under the surface using surface profilometry. Although osteoclast formation was similar in M-CSF + RANKL-treated
cultures between the groups (𝑝 > 0.05), there was a significant increase in the area of resorption on the surface (𝑝 < 0.01) and
under the surface (𝑝 < 0.01) in Charcot patients compared with diabetic patients and control subjects. The addition of anti-TNF-𝛼
resulted in a significant reduction in the area of resorption on the surface (𝑝 < 0.05) and under the surface (𝑝 < 0.05) only in
Charcot patients as well as a normalisation of the aberrant erosion profile. We conclude that TNF-𝛼modulates RANKL-mediated
osteoclastic resorption in vitro in patients with acute Charcot osteoarthropathy.
1. Introduction
Charcot osteoarthropathy is a severe complication of dia-
betes, which is associatedwith significantmorbidity andmor-
tality [1–5]. Inflammation and increased osteoclastic activity
are well-recognised drivers of the rapid bone destruction that
occurs in the Charcot foot, although the link between them
is not fully understood [6].
We have recently demonstrated that, in acute Charcot
osteoarthropathy, there is increased osteoclastic activity in
response to the osteoclastogenic cytokine receptor activator
of nuclear factor-𝜅𝛽 ligand (RANKL) [7]. Osteoclasts, gen-
erated from peripheral blood monocytes of Charcot patients
in the presence of the stimulating factor macrophage-colony
stimulating factor (M-CSF) and RANKL, excessively resorb
bone slices.Using the novel technique of surface profilometry,
in addition to traditional light microscopy, we have shown
that osteoclasts derived from Charcot patients eroded bone
surfaces with an aberrant pit profile and geometry [8].
Resorption pits from cultures of Charcot patients appeared
more frequently as multidented pits and were significantly
deeper and wider compared with resorption pits in healthy
controls [8].
The reason for this increased resorbing activity is
unknown, but it is possible that it is driven by uncon-
trolled inflammation due to upregulation of proinflammatory
cytokines and in particular tumour necrosis factor-𝛼 (TNF-
𝛼) [6]. As an osteoclastogenic mediator, TNF-𝛼 induces
expression of RANKL in osteoblastic cells, but it can also act
directly on osteoclastic precursors (monocytes) to potentiate
RANKL-induced osteoclastogenesis and thereby activity [9].
This cytokine is known to enhance osteoclastogenesis in
rheumatoid arthritis [10, 11] and psoriatic arthritis [12] and
also in other forms of inflammatory osteolysis [13] and we
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hypothesised that TNF-𝛼 may also modulate osteoclastic
activity in acute Charcot osteoarthropathy. Thus the aim of
this study was to determine the role of this cytokine by
comparing the extent of osteoclast formation and resorption
in M-CSF + RANKL-treated cultures with and without the
addition of neutralising antibody to TNF-𝛼 (anti-TNF-𝛼).
2. Materials and Methods
2.1. Patients. Samples from peripheral blood were obtained
from 10 consecutive patients with recent onset of acute
Charcot osteoarthropathy, 8 diabetic patients with no history
of Charcot osteoarthropathy, and 9 healthy control subjects.
All patients with Charcot osteoarthropathy presented with
a unilateral red hot swollen foot and radiological evidence
of acute Charcot fractures, demonstrated on plain foot and
ankle radiographs [1, 5]. All participants had intact feet and
had no features of foot infection or sepsis. The study was
approved by the Outer West London Research Ethics Com-
mittee and was carried out in accordance with institutional
guidelines and the Declaration of Helsinki with all patients
and control subjects signing written informed consent.
2.2. Isolation and Culture of Peripheral Blood Mononu-
clear Cells (PBMCs). Peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood as previously
described [8]. The PBMCs were separated after gradient
centrifugation and resuspended in culture medium and 2 ×
106 cells were cultured on 24-well plates and 5 × 105 cells were
cultured on bovine bone discs (Immunodiagnostic Systems
Ltd., Boldon, UK) in duplicate to assess osteoclast formation
and resorption, respectively. Cultures were maintained in 𝛼-
minimal essential medium (𝛼-MEM, Lonza, Wokingham,
UK) supplemented with penicillin (50U/mL)/streptomycin
(50𝜇g/mL) (Sigma-Aldrich Ltd., Poole, UK), L-glutamine
(2mM) (Sigma-Aldrich Ltd., Poole, UK), and 10% heat-
inactivated FBS (Lonza Ltd., Wokingham, UK) under the
following conditions:
(i) Cultures with M-CSF 25 ng/mL (added at day 0)
(R&D Systems Europe, Ltd., Abingdon, UK) and sol-
uble RANKL 100 ng/mL (added at day 7) (PeproTech
EC Ltd., London, UK): M-CSF + RANKL-treated
cultures served as a positive control.
(ii) Cultures with M-CSF (added at day 0), anti-TNF-𝛼
10 𝜇g/mL (added at day 0), (R&D Systems Europe,
Ltd., Abingdon, UK), and soluble RANKL 100 ng/mL
(added at day 7): M-CSF + RANKL + anti-TNF-𝛼-
treated cultures were used to assess the role of TNF-
𝛼 on osteoclastogenesis. The rationale for this study
was to inhibit TNF-𝛼modulation on peripheral blood
monocytes by using excess concentration of anti-
TNF-𝛼, added from the beginning until the end of the
cell culture treatment [14].
Culture medium was refreshed every 3-4 days supplemented
with the appropriate agents as described above. After 17
days in culture, 24-well plates were stained for tartrate-
resistant acid phosphatase (TRAP). Plates were viewed by
light microscopy and TRAP-positive cells with three or more
nuclei were counted as osteoclasts. The ability of these cells
to resorb bone was demonstrated by culturing PBMCs on
bovine bone discs for 21 days. The bone discs were stained
with toluidine blue and mounted on glass slides. Resorption
was quantitated by twomethods: (1) area of resorption on the
surface (%) assessed by image analysis after light microscopy
and (2) area of resorption under the surface (𝜇m2) assessed by
surface profilometry, as previously described [8].The erosion
profile of resorbed bone discs was measured by the Dektak
150 Surface Profiler (Veeco, New York, USA) fitted with a
stylus (radius 2.5 𝜇m), as previously described [8]. The stylus
was dragged across the surface of the sample in hills and
valleysmodewith ten scans per subject carried out at random
sites on each of the two discs. Each measurement had the
following scan parameters: stylus force: 3.00mg, scan length:
1000 𝜇m, scan duration: 60 seconds, vertical measurement
range: 65.5𝜇m, scan resolution: 0.056𝜇m/scan. On average,
75 pits per condition/per subject were analysed and the
median area of disc erosion was calculated in 𝜇m2 using
Origin Pro 8.6 software.
According to their shape, pits were defined as unidented
(erosion with one dent starting from and finishing at the
level of the unresorbed surface), bidented (erosion with two
clearly defined dents starting from and finishing at the level
of the unresorbed surface), and multidented (erosion with
three or more dents starting from and finishing at the level
of the unresorbed surface). Each pit was characterised by the
following parameters: width at the surface (𝜇m), maximum
depth (𝜇m), and full-width-half-maximum (FWHM) (𝜇m),
where the width was measured at the half of the maxi-
mum depth. The median width, depth, and FWHM for the
unidented, bidented, andmultidented pits were calculated for
each subject [8].
2.3. Statistical Analyses. Data were analysed with Predictive
Analytics Software 18 statistical package and expressed as
median (25th–75th percentile). Differences between study
groups and culture treatments were analysed using the non-
parametric Mann-Whitney 𝑈 test (two groups) or Kruskal-
Wallis test (three groups), as appropriate. Chi-square test was
used for categorical variables. Differences were considered
significant at 𝑝 < 0.05.
3. Results
3.1. Demographical Features. Patients with acute Charcot
osteoarthropathy were matched for age, gender, and type
and duration of diabetes with the diabetic patients and for
age and gender with the healthy control subjects. The age,
gender distribution, and type and duration of diabetes were
not significantly different between the Charcot patients and
diabetic patients nor were the age and gender distribution
between the Charcot patients and healthy control subjects
(Table 1).
3.2. Osteoclast Formation. Observation of the cell culture
plates with light microscopy showed no difference in osteo-
clast formation inM-CSF+RANKL-treated cultures between
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Table 1: Demographic features of the study patients.
Charcot Diabetes Healthy control subjects
Age (years) 57 [53–64] 60 [55–66] 45 [42–48]
Gender (male : female) 6 : 4 3 : 4 5 : 3
Type 1 : type 2 diabetes 4 : 6 1 : 6 —
Duration of diabetes (years) 17 [8–29] 10 [9–26] —
Data expressed as median [25th–75th percentile].
Nonsignificant difference in age, gender distribution, type and duration of diabetes (Charcot patients versus diabetic patients), and age and gender (Charcot
patients versus healthy control subjects); (𝑝 > 0.05 for all pairwise comparisons).
the three groups (Figure 1(a)).Themedian number of TRAP-
positive multinucleated cells in M-CSF + RANKL-treated
cultures in Charcot patients was not significantly different
from the median number of TRAP-positive multinucle-
ated cells in diabetic patients and healthy control subjects
(Figure 1(b)).
The addition of anti-TNF-𝛼 to M-CSF + RANKL treat-
ment did not lead to a significant difference in the median
number of TRAP-positive multinucleated cells in Charcot
patients, diabetic patients, and healthy control subjects (Fig-
ures 1(a) and 1(b)).
3.3. Osteoclast Resorption. Traditional light microscopy
(Figure 1(c)) together with surface profilometry revealed
that the newly formed osteoclasts isolated from patients
with acute Charcot osteoarthropathy exhibited increased
resorbing activity in M-CSF + RANKL-treated cultures
compared with osteoclasts generated from diabetic patients
and healthy controls, as indicated by a significantly increased
area of resorption on the surface (Figure 1(d)) and under the
surface (Figure 1(e)).
The addition of anti-TNF-𝛼 to M-CSF + RANKL treat-
ment led to a significant reduction in the area of resorption
on the surface (Figures 1(c) and 1(d)) and under the surface
(Figure 1(e)) only in Charcot patients but not in diabetic
patients or healthy control subjects. In Charcot patients, the
area of resorption on the surface assessed by image analysis
was 30% smaller in M-CSF + RANKL + anti-TNF-𝛼-treated
cultures compared with M-CSF + RANKL-treated cultures
(Figure 1(d)) as was the area of resorption under the surface
after surface profilometry (Figure 1(e)).
3.4. Erosion Profile of Resorbed Bovine Bone Discs after
Surface Profilometry. The surface profile measurements of
randomly selected areas revealed multishaped erosions of
resorbed bovine bone discs in all study groups in both culture
treatments (Figures 2(a) and 2(b)).
However, in M-CSF + RANKL-treated cultures, the
erosion profiles were markedly different between the three
groups (Figure 2(a)). The erosions appeared greater and
deeper in Charcot patients compared to erosions in diabetic
patients and healthy controls (Figure 2(a)).
After the addition of anti-TNF-𝛼 to M-CSF + RANKL
treatment, the observed differences in the erosion profile
between the three groups were lost (Figure 2(b)). In Charcot
patients, there was a “normalisation” of the erosion profile
in M-CSF + RANKL + anti-TNF-𝛼-treated cultures com-
pared to M-CSF + RANKL-treated cultures (Figure 2(c)),
whereas anti-TNF-𝛼 had no effect on the erosion profiles
of diabetic patients (Figure 2(d)) or healthy control subjects
(Figure 2(e)).
3.5. Pit Morphology. To assess in more detail the differences
in resorption under the surface, pit morphology was evalu-
ated. InM-CSF+RANKL-treated cultures, the pit parameters
(median width, FWHM and depth) were greater in Charcot
patients compared with diabetic patients and healthy control
subjects (Figures 2(f), 2(g), and 2(h)). The addition of anti-
TNF-𝛼 to M-CSF + RANKL treatment led to a significant
reduction in the width, FWHM, and depth of the unidented
pits in Charcot patients (Figure 2(f)). Although the reduction
of the bidented pit parameters (Figure 2(g)) and multidented
pit parameters (Figure 2(h)) was not significant, there was a
general trend of “normalisation” of pits after anti-TNF-𝛼. In
contrast to Charcot patients, the addition of anti-TNF-𝛼 had
no effect on pit parameters in diabetic patients or in healthy
control subjects (Figures 2(f), 2(g), and 2(h)).
3.6. Pit Distribution. To determine whether there were any
differences in the distribution of the shape of the pits,
the percentage of unidented, bidented, and multidented
pits between the two culture treatments was compared. In
Charcot patients, the addition of anti-TNF-𝛼 to M-CSF +
RANKL resulted in a significant increase in the percentage of
unidented pits (from 36% [31–43] to 53% [43–63], 𝑝 < 0.05)
and a significant decrease in the percentage of multidented
pits (from 40% [32–42] to 25% [13–33], 𝑝 < 0.05), whereas
the percentage of bidented pits remained unchanged (from
24% [20–28] to 22% [21–24], 𝑝 > 0.05) (Figure 2(i)).
There was no significant difference in the distribution of
pits (unidented, bidented, and multidented) between the two
culture treatments in the diabetic patients and in the healthy
controls (Figure 2(i)).
4. Discussion
This in vitro study has shown that there was a significant
reduction in the resorbing activity of M-CSF + RANKL-
treated osteoclasts derived from Charcot patients in response
to anti-TNF-𝛼 treatment.The addition of anti-TNF-𝛼 resulted
in significant reduction in the area of resorption on bovine
bone discs both on the surface, as assessed by image analysis,
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Figure 1: Osteoclast formation and resorption in Charcot patients, diabetic patients, and healthy control subjects inM-CSF +RANKL-treated
cultures and in M-CSF + RANKL + anti-TNF-𝛼-treated cultures. Representative images of TRAP-positive multinucleated cells formed on
plastic (Olympus; originalmagnification×100, scale bar = 200 𝜇m) (a) and resorbed bovine bone discs (Olympus BX60; originalmagnification
×200) (c). The arrows denote some of the TRAP-positive multinucleated cells (a) and some of the resorption pits (c). Comparison of the
number of TRAP-positive multinucleated cells (b), the area of resorption at the surface (d), and the area of resorption under the surface (e)
of resorbed bone discs between M-CSF + RANKL-treated cultures (white bars) and M-CSF + RANKL + anti-TNF-𝛼-treated cultures (grey
bars). Significance assessed by Mann-Whitney 𝑈 test, levels of significance are demonstrated on the graphs; ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ns =
nonsignificant (𝑝 > 0.05).
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Figure 2: Surface profilometry in Charcot patients, diabetic patients, and healthy control subjects inM-CSF +RANKL-treated cultures and in
M-CSF+RANKL+ anti-TNF-𝛼-treated cultures. Representative erosion profiles of resorbed bone discs inCharcot patient (blue line), diabetic
patient (red line), and healthy control subject (green line) after surface profilometry inM-CSF + RANKL-treated cultures (a) and inM-CSF +
RANKL + anti-TNF-𝛼-treated cultures (b). Representative erosion profiles of resorbed bone discs in M-CSF + RANKL-treated cultures
(blue line) and M-CSF + RANKL + anti-TNF-𝛼-treated cultures (red line) in Charcot patient (c), diabetic patient (d), and healthy control
subject (e). The marked difference of the erosion profile in a Charcot patient compared with diabetic patient and healthy control in MCSF +
RANKL-treated cultures (a) was reversed after the addition of anti-TNF-𝛼 (b). Pits appeared significantly smaller in M-CSF + RANKL +
anti-TNF-𝛼-treated cultures compared with MCSF + RANKL-treated cultures in Charcot patients (c) but remained unchanged in diabetic
patients (d) and in healthy controls (e). Comparison of pit measurements (width, FWHM, and depth) between M-CSF + RANKL-treated
cultures (white bars) and M-CSF + RANKL + anti-TNF-𝛼-treated cultures (grey bars); unidented pits (f), bidented pits (g), and multidented
pits (h). Significance assessed by Mann-Whitney 𝑈 test, levels of significance are demonstrated on the graphs; ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ns =
nonsignificant (𝑝 > 0.05). Distribution of pits (%) according to their shape inM-CSF + RANKL andM-CSF + RANKL + anti-TNF-𝛼-treated
cultures in Charcot patients, diabetic patients, and healthy control subjects (i). In M-CSF + RANKL-treated cultures, there was a significant
reduction in the percentage of unidented (𝑝 < 0.05) and a significant increase in the percentage of multidented pits (𝑝 < 0.05) in Charcot
patients compared with diabetic patients and healthy controls. The addition of anti-TNF-𝛼 treatment led to a significant difference in the pit
distribution only in Charcot patients characterised by a significant increase in the percentage of unidented pits (𝑝 < 0.05) and significant
decrease in the percentage of multidented pits (𝑝 < 0.05). No differences in the pit distribution were noted in diabetic patients and in healthy
control subjects.
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and also under the surface, as assessed by surface profilom-
etry. The aberrant erosion profile, pit morphology, and pit
distribution in M-CSF + RANKL-treated cultures in Charcot
patients were reversed after the addition of anti-TNF-𝛼.These
findings confirm the hypothesis that the proinflammatory
cytokine TNF-𝛼 modulates increased osteoclastic activity in
acute Charcot osteoarthropathy.
In the present study, we have shown that newly derived
osteoclasts from monocytes isolated from Charcot patients
exhibit an enhanced response to RANKL. Osteoclastogenesis
is pivotally dependant on M-CSF (a survival factor) and
RANKL (key factor for osteoclast differentiation and regula-
tion) [15, 16]. In the presence of these two cytokines, mono-
cytes, which express the receptors c-fms and RANK, prolif-
erate and differentiate into mature multinucleated osteoclasts
[17, 18].The osteoclasts generated fromCharcot patients were
functionally more aggressive compared to osteoclasts from
diabetic patients and healthy control subjects in a classical
resorption assay [7, 8]. In addition, surface profilometry
demonstrated that osteoclasts from Charcot patients exhib-
ited a considerable below-surface resorbing activity, which
was not associated with an increase in osteoclast formation
[8]. However, the mechanisms of this enhanced response are
unknown.
In Charcot osteoarthropathy bone loss is limited to the
inflamed affected foot [19, 20] and it is possible that local
inflammatory factors released after initial trauma to the
Charcot foot may act as osteoclastogenic mediators [6]. In
this study, we sought to determine the role of TNF-𝛼 as
a promoter of the observed enhanced osteoclast function.
This cytokine has been linked with inflammatory bone loss
[12] and immunohistochemical analysis of surgical Charcot
specimens has indicated that osteoclastic bone resorption
takes place in the presence of TNF-𝛼 [21]. In the acute
stage of the osteoarthropathy, serum concentrations of TNF-
𝛼 are raised [22]. Moreover, in the acute Charcot foot,
inflammatory modulation of peripheral monocytes with
increased spontaneous and induced production of TNF-𝛼has
been noted [23]. In this study, using the traditional resorp-
tion pit assay together with surface profilometry, we have
demonstrated that although osteoclast formation remained
unchanged, the addition of anti-TNF-𝛼 toM-CSF + RANKL-
treated cultures significantly decreased osteoclast function.
This is in agreement with previous data showing that TNF-
𝛼 is more potent for osteoclast activation than for osteoclast
formation [24]. The inhibition of TNF-𝛼 led to a significant
reduction in the area of resorption on the surface and under
the surface in cultures from Charcot patients.
As well as increased resorption, in our study, there were
a pathological erosion profile and aberrant morphological
appearance of resorption pits on bone slices in M-CSF +
RANKL-treated cultures in Charcot patients compared with
healthy control subjects [8] and also in Charcot patients
compared with diabetic patients. We demonstrated that the
addition of anti-TNF-𝛼 reversed the observed differences in
pit parameters and erosion profile between the study groups
and in Charcot patients there was a notable “normalisation”
of the erosion profile and pit morphology. This suggests that
osteoclasts generated in M-CSF + RANKL-treated cultures,
prior to inhibition of TNF-𝛼, exhibit a highly aggressive
resorptive profile. This exuberant resorptive activity was
reduced after the addition of anti-TNF-𝛼, providing further
evidence to support the role of this cytokine in the osteoclas-
togenesis of acute Charcot osteoarthropathy.
As well as changes in the morphological appearance
of pits, there was a difference in the distribution of the
shape of the pits in Charcot patients between the two
culture treatments. The resorption pits in M-CSF + RANKL-
treated cultures of the Charcot patients were predominantly
multidented and bidented whilst the unidented pits were less
frequently seen although in diabetic patients and in healthy
control subjects the pit distribution remained unchanged
between the two culture treatments.
The addition of anti-TNF-𝛼 to M-CSF + RANKL-treated
cultures resulted in a significant reduction in the percentage
of the multidented pits as well as a significant increase the
percentage of the unidented pits.Thus, the inhibition of TNF-
𝛼 normalised the resorptive behaviour of Charcot osteoclasts
in which resorption alternated with migration as indicated
by a significant increase in the percentage of unidented
pits. It is possible that observed aberrant pit morphology
and distribution were due to a TNF-𝛼 modulation of the
resorption cycle (Figure 3(a)). During the process of bone
resorption, osteoclasts solubilise bone mineral followed by
degradation of demineralised organic matrix and in control
conditions, the relative rate of collagenolysis is slower than
the rate of demineralisation [25]. Experimental in vitro stud-
ies have shown that agents which can upregulate cathepsin K
expression prolong the resorption cycle and resorption events
more frequently present as trenches (continuous resorption)
[25]. In contrast, inhibition of cathepsin K accelerates the
resorption cycle, leading to faster accumulation of collagen.
This results in resorption events more frequently presenting
as shallower and smaller pits (intermittent resorption). Both
RANKL and TNF-𝛼 stimulate the osteoclasts to produce
cathepsin K, which is the major protease responsible for the
degradation of collagen [26]. In Charcot osteoarthropathy
it is possible that TNF-𝛼 via enhanced cathepsin K expres-
sion may lead to imbalance between the relative rate of
collagenolysis and demineralisation. This mechanism may
explain the continuous resorptions which we observed as
multidented pits in the M-CSF + RANKL-treated cultures in
contrast to the more frequently noted intermittent resorp-
tions (unidented pits) after the addition of anti-TNF-𝛼 [25]
(Figure 3(a)).
These findings have important implications for under-
standing the pathogenesis of this condition. Our data under-
scores the potent role of TNF-𝛼 in the RANKL-mediated
osteoclastogenesis (Figure 3(b)). Trauma to the neuropathic
diabetic foot leads to bone damage and uncontrolled inflam-
mation [6]. Bone fracture is the harbinger of Charcot
osteoarthropathy [27] and it leads to changes in the bone
matrix, which becomes a site of targeted remodelling with
increased numbers of apoptotic osteocytes (bone matrix
cells) and rapid degradation by activated osteoclasts [18, 28].
Furthermore, bone fracture triggers a coordinated healing
cytokine response with the induction of proinflammatory
cytokines, including TNF-𝛼 [29]. In the affectedCharcot foot,
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Figure 3: Model for osteoclast resorptive activity in Charcot osteoarthropathy in M-CSF + RANKL-treated cultures before and after the
addition of anti-TNF-𝛼 (a). In the presence of TNF-𝛼, continuous multidented pits (defined as lacunae or trenches) with increased area of
resorption both on the surface and under the surface are seen more frequently compared with less frequently noted unidented pits (single
resorption event). Resorption is prolonged and is not interrupted by migration episodes. After the inhibition of TNF-𝛼, the percentage
of multidented pits is reduced with a corresponding increase in the percentage of unidented pits suggesting that the resorptive cycle is
restored. Resorption alternates with migration and intermittent resorption events occur away from each other (unidented pits).The observed
differences in the resorption before and after the addition of anti-TNF-𝛼 suggest that TNF-𝛼 (via cathepsin K upregulation) modulates
the resorptive behaviour of osteoclasts generated from Charcot patients and these highly active osteoclasts are capable of extensive lacunar
resorption with aberrant pit morphology and geometry due to reduced migration, increased survival, and reduced apoptosis. The proposed
role of TNF-𝛼 in the pathogenesis of pathological bone destruction in the acute Charcot foot (b).
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the inflammatory response to traumawith increased cytokine
release leads to an upregulation of receptors and adhesion
molecules in the endothelium which then forms a firm
attachment to osteoclast precursors resulting in enhanced
recruitment of osteoclasts to sites of bone resorption [30].
Furthermore, the activation of RANK by RANKL attracts
osteoclastic precursors [31] and its upregulation contributes
to an enhanced RANKL-induced monocyte migration to the
affected foot. Thus TNF-𝛼-primed osteoclastic precursors
in the presence of increased local expression of RANKL
differentiate into highly aggressive osteoclasts with extensive
resorbing activity characterised by increased survival and
reduced apoptosis and migration. This increased osteoclastic
activity may be due to cathepsin K upregulation, which
requires further studies, as this may provide scientific basis
for novel intervention with cathepsin K inhibitors. Overall,
these aberrantly activated osteoclasts play a key role in the
pathological bone destruction of the acute Charcot foot.
In conclusion, using a traditional osteoclast resorp-
tion assay together with surface profilometry, this study
has demonstrated for the first time that the proinflamma-
tory cytokine TNF-𝛼 modulated RANKL-mediated osteo-
clastic resorption in vitro in patients with acute Charcot
osteoarthropathy and these observations shed light into the
pathogenesis of this devastating condition.
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